Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. However, immunocompromised individuals have been excluded from studies of SARS-CoV-2 vaccines. In such patients, the immune response to vaccination may be blunted. To better understand the immunogenicity of SARS-CoV-2 vaccines in transplant recipients, we quantified the humoral response to SARS-CoV-2 vaccine in kidney transplant recipients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| kidney transplant recipients | kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| seropositive anti-COVID-19 antibody | seropositive anti-COVID-19 antibody, including IgM, IgG, and IgA | 2 to 6 weeks after the second injection of inactivated vaccine |
Not provided
Not provided
Inclusion Criteria:
Receiving kidney transplantation in West China Hospital, Sichuan University
Exclusion Criteria:
1) History of rejection or infection over the previous 3 months; 2) receiving kidney transplantation >3 months; 3) Combined with HBV/HVC/HIV infection in the donor or recipient; 4) Malignancy history in the donor and recipient; 5) organ transplant history in the recipient.
Not provided
Not provided
patients receiving kidney transplantation in West China Hospital between 01/01/2015 and 01/03/2021
Not provided
Not provided
Not provided
Not provided